GlassScriptPhysician profile
Maresa E Muhlethaler
NPI 1952629792
$3,720.30
in general payments reported to CMS, 2019-2025
31 companies · $784 in 2025
The $784 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $578 · 2022: $341 · 2023: $1,246 · 2024: $771 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,633 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,632.51 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $585.63 | 2021-2025 | Breztri, Tezspire, Airsupra |
| Abbvie INC. | $529.20 | 2021-2025 | |
| Lilly USA, LLC | $358.04 | 2021-2024 | Mounjaro |
| Novo Nordisk INC | $351.09 | 2021-2023 | Wegovy |
| Astellas Pharma US INC | $281.56 | 2023-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $170.55 | 2024-2025 | Caplyta |
| Inspire Medical Systems, INC. | $144.28 | 2023-2024 | Inspire |
| Paratek Pharmaceuticals, INC. | $141.34 | 2024 | Nuzyra |
| Axsome Therapeutics, INC. | $126.18 | 2022-2025 | Auvelity |
| Pulmonx Corporation | $122.68 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Vanda Pharmaceuticals INC. | $119.84 | 2024-2025 | Fanapt |
| Globus Medical, INC. | $82.87 | 2025 | Senza |
| Phathom Pharmaceuticals, INC. | $81.61 | 2025 | Voquezna |
| Avadel Cns Pharmaceuticals, LLC | $72.61 | 2023 | Lumryz |
| Glaxosmithkline, LLC. | $68.51 | 2023 | Arexvy, Trelegy Ellipta, Shingrix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $61.32 | 2023 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $54.52 | 2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $51.28 | 2023 | |
| Novartis Pharmaceuticals Corporation | $47.05 | 2024 | |
| Gilead Sciences, INC. | $42.16 | 2021 | |
| Genentech USA, INC. | $39.00 | 2021 | |
| Mylan Specialty L.P. | $30.70 | 2021 | |
| Amgen INC. | $29.17 | 2024-2025 | Evenity, Prolia, Prolia |
| Exact Sciences Corporation | $24.56 | 2024 | Cologuard Collection Kit |
| Insulet Corporation | $19.25 | 2023 | Omnipod |
| Janssen Pharmaceuticals, INC | $17.60 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.47 | 2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.95 | 2024 | Xifaxan |
| Eisai INC. | $12.42 | 2021 | |
| Dexcom, INC. | $11.94 | 2021 | |
| Amarin Pharma, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maresa Muhlethaler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.